Trials Sponsors Conditions Drugs Pricing

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
up to 4 days
Maximum measured concentration of the analyte in plasma (Cmax)
up to 4 days

Secondary Outcomes (1)

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
up to 4 days

Study Arms (2)

Treatment sequence 1

EXPERIMENTAL

Sequence: 1. \- Reference treatment (BI 3000202) 2. \- Test treatment 1 (BI 3000202 + Ciclosporin) 3. \- Test treatment 2 (BI 3000202 + Itraconazole)

Drug: BI 3000202Drug: CiclosporinDrug: Itraconazole

Treatment sequence 2

EXPERIMENTAL

Sequence: 1. \- Test treatment 1 (BI 3000202 + Ciclosporin) 2. \- Reference treatment (BI 3000202) 3. \- Test treatment 2 (BI 3000202 + Itraconazole)

Drug: BI 3000202Drug: CiclosporinDrug: Itraconazole

Interventions

BI 3000202Drug

BI 3000202

Treatment sequence 1Treatment sequence 2

CiclosporinDrug

Ciclosporin

Treatment sequence 1Treatment sequence 2

Eligibility Criteria

Age18 Years - 55 Years

Sexmale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Healthy male trial participant according to the assessment of the investigator, as based on a complete medical history, physical examination, vital signs (Blood pressure, Pulse rate), 12-lead Electrocardiogram, and clinical laboratory tests
Age of 18 to 55 years (inclusive)

Sponsors & Collaborators

Boehringer Ingelheim
Industrylead
Boehringer Ingelheim International GmbH
Industrylead

Study Sites (1)

Humanpharmakologisches Zentrum Biberach

Biberach, 88397, Germany

MeSH Terms

Interventions

CyclosporineItraconazole

Intervention Hierarchy (Ancestors)

CyclosporinsPeptides, CyclicMacrocyclic CompoundsPolycyclic CompoundsPeptidesAmino Acids, Peptides, and ProteinsTriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPiperazines

Study Design

Study Type: interventional
Phase: phase 1
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: CROSSOVER
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 17, 2026

First Posted

August 19, 2026

Study Start

September 1, 2026

Actual (reported)

Primary Completion

October 6, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (2)

Treatment sequence 1

Treatment sequence 2

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source records

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (2)

Treatment sequence 1

Treatment sequence 2

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source records

Locations